This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Down -29.25% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Adverum Biotechnologies (ADVM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Adverum Biotechnologies (ADVM) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Here's Why You Should Invest in Adverum (ADVM) Stock Now
by Zacks Equity Research
Here, we discuss some reasons why buying Adverum Biotechnologies (AQST) stock now may turn out to be a prudent move.
Is Adial Pharmaceuticals (ADIL) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Adial Pharmaceuticals, Inc. (ADIL) and Adverum Biotechnologies (ADVM) have performed compared to their sector so far this year.
Adverum (ADVM) Doses First Patient in the Mid-Stage wAMD Study
by Zacks Equity Research
Adverum (ADVM) initiates dosing in the phase II LUNA study, currently investigating its lead product candidate ixoberogene soroparvovec for wet age-related macular degeneration.
Adverum (ADVM) Completes IND Amendment for Gene Therapy Study
by Zacks Equity Research
Adverum (ADVM) completes IND amendment with the FDA for initiating the phase II LUNA study on its gene therapy candidate, ADVM-022, for treating wet-age-related macular degeneration. Stock up.
Adverum (ADVM) Up on FDA Feedback for Gene Therapy Study
by Zacks Equity Research
Adverum (ADVM) to submit IND amendment to the FDA by mid-2022 for starting a mid-stage study on its gene therapy candidate ADVM-022 for treating wet AMD eye disorder.
Should You Buy Adverum Biotechnologies (ADVM) Ahead of Earnings?
by Zacks Equity Research
Adverum Biotechnologies (ADVM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Adverum Biotechnologies (ADVM) Might Surprise This Earnings Season
by Zacks Equity Research
Adverum Biotechnologies (ADVM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in Store for Harrow Health (HROW) in Q2 Earnings?
by Zacks Equity Research
Harrow Health (HROW) Q2 results are likely to reflect growth coming from the launch of Visionology, the company's direct-to-consumer eyecare platform.
BioNTech (BNTX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On BioNTech's (BNTX) second-quarter earnings call, investors' focus will be on sales number of BNT162b2, its COVID-19 vaccine, developed in partnership with Pfizer.
Novavax (NVAX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Novavax's (NVAX) upcoming second-quarter earnings call, investor focus is likely to be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.
Bionano (BNGO) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Bionano Genomics (BNGO) is likely to provide updates on earnings and revenues when it reports second-quarter 2021 results.
Adverum Biotechnologies (ADVM) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Adverum Biotechnologies (ADVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Options Traders Betting on a Big Move in Adverum (ADVM) Stock?
by Zacks Equity Research
Investors need to pay close attention to Adverum (ADVM) stock based on the movements in the options market lately.
Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase
by Zacks Equity Research
Dr. Reddy's (RDY) earnings decline while sales grow year over year in fourth-quarter fiscal 2021.
Adverum Biotechnologies (ADVM) is Oversold: Can It Recover?
by Zacks Equity Research
Adverum Biotechnologies (ADVM) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Adverum Biotechnologies (ADVM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of 23.68% and 1530.44%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Is the Options Market Predicting a Spike in Adverum Biotechnologies (ADVM) Stock?
by Zacks Equity Research
Investors need to pay close attention to Adverum Biotechnologies (ADVM) stock based on the movements in the options market lately.
Adverum Biotechnologies (ADVM) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of -21.88% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About Adverum Biotechnologies (ADVM) Rating Upgrade to Buy
by Zacks Equity Research
Adverum Biotechnologies (ADVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Implied Volatility Surging for Adverum Biotechnologies (ADVM) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Adverum Biotechnologies (ADVM) stock based on the movements in the options market lately.
Adverum Biotechnologies (ADVM) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of 11.43% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Adverum Biotechnologies (ADVM) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Adverum Biotechnologies (ADVM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Adverum Biotechnologies (ADVM) Stock?
by Zacks Equity Research
Investors need to pay close attention to Adverum Biotechnologies (ADVM) stock based on the movements in the options market lately.